Tuesday, October 15, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Oracle (ORCL) and Novo Nordisk (NVO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Intel’s shares have outperformed the Zacks General Semiconductor industry year to date (3.1% vs. -6.4%). The Zacks analyst believes that Intel is benefiting from rising demand witnessed in its higher performance products, both in data center and client domains.
Moreover, synergies from its Mobileye acquisition and growing clout in ADAS market favor the company’s growth prospects. Further, Intel’s strategy of expanding TAM beyond CPU to adjacent product lines like silicon photonics, fabric, network ASICs, and 3D XPoint memory is yielding results.
The launch of its new 10nm-technology-based AI chip, Springhill, holds promise. However, weakness in demand from China and softness in NAND flash pricing trends, expenses pertaining to 10-nanometer (nm) ramp and constrained supply remain major concerns. Moreover, intensifying competition and pricing pressure from AMD remains a headwind.
(You can read the full research report on Intel here >>>)
Shares of Oracle have gained 3.4% in the past six months, compared with the Zacks Computer Software industry’s rise of 8.2%. The Zacks analyst believes that Oracle is benefiting from strong adoption of cloud-based solutions, comprising NetSuite ERP, Fusion ERP and Fusion HCM, among others.
Partnerships with the likes of Accenture and Microsoft are expected to aid Oracle in expanding cloud-based clientele. Moreover, strong demand for the latest autonomous database supported by ML is likely to bolster the top line and provide a competitive edge against Amazon Web Services (AWS) in the Database-as-a-Service market.
Nonetheless, stiff competition in the cloud market from dominant players is anticipated to weigh on profits. Further, lower hardware volumes are expected to hurt the top line, keeping margins under pressure. Additionally, integration risks from buyouts remain a concern. Notably, shares of Oracle have underperformed the industry in the past year.
(You can read the full research report on Oracle here >>>)
Novo Nordisk’s shares have gained 9% over the past three months, compared with the Zacks Biotech industry’s rise of 0.4%. The Zacks analyst believes a solid performance from Tresiba, Victoza, Ozempic, Xultophy and Saxenda have driven the company’s sales in the year so far.
Label expansion of Victoza continues to boost performance. Ozempic, the company’s once-weekly GLP-1, continues to gain market share. The FDA recently approved semaglutide in tablet form under the brand name, Rybelsus. The company continues to evaluate the candidate for multiple indications. Shares of the company have outperformed the industry year to date.
However, lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy and intensifying competition within the diabetes and biopharmaceuticals markets will adversely impact sales, going ahead.
(You can read the full research report on Novo Nordisk here >>>)
Other noteworthy reports we are featuring today include ConocoPhillips (COP), Occidental Petroleum (OXY) and Advanced Micro Devices (AMD).
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Intel (INTC) Rides on AI-based Alliances & Product Rollouts
Oracle (ORCL) Gains from Cloud Suite Adoption & Partnerships
Novo Nordisk (NVO) Diabetes Business Strong Amid Competition
ConocoPhillips (COP) to Focus on US Shale Post Athena Sale
The Zacks analyst believes that ConocoPhillips' Australia-West asset divestment, including the Athena field, is likely to enable it to generate more value from US shale amid surging operating costs.
AMD Benefits From GPU Product Rollouts & Partnerships
Per the Zacks analyst, Advanced Micro's release of Radeon RX Vega family of GPUs and alliance with companies like Baidu, Amazon, Tencent, Microsoft and JD.com will drive the top and bottom line.
CBRE Group (CBRE) to Ride High With Strategic Acquisitions
Per the Zacks Analyst, CBRE Group will ride high on buyouts that expand and reinforce service offerings and enhance geographic reach.
AmerisourceBergen's (ABC) World Courier Up Amid Competition
AmerisourceBergen gains ground on its World Courier business. The Zacks Analyst is pessimistic about cutthroat competition in the MedTech Space.
Cheniere Energy's (LNG) Gas Export Dominance Bodes Well
The Zacks analyst likes Cheniere's competitive advantage of being the first and dominant natural gas exporter in the U.S. market.
Growing Top-line Aid WellCare Health (WCG), High Costs Hurt
Per the Zacks analyst, its growing revenues driven by premium growth and accretive acquisitions has led to significant growth.
Buyouts Aid Jones Lang (JLL) Amid Muted Transaction Volumes
Per the Zacks Analyst, strategic acquisitions will boost Jones Lang LaSalle's business and drive inorganic growth. Yet, low real estate transaction volumes is a concern.
Skechers' (SKX) Robust International Business to Drive Sales
Per the Zacks analyst, Skechers' international wholesale business remains a key sales driver. Management expects international business to increase at a mid-teens rate over the balance of the year.
Gol Linhas (GOL) Rides High on Solid Passenger Unit Revenues
The Zacks analyst is impressed by the robust rise in passenger unit revenues on the back of strong travel demand. The company's focus on capacity discipline is also aiding its performance.
Solid Assets Balance Aid Cohen & Steers (CNS) Revenue Growth
Per the Zacks analyst, Cohen & Steers' revenues will continue to grow driven by robust assets balance, diverse product offerings and investment strategies. Its capital deployments remain impressive.
Rising Global Freight Rates Will Hurt Occidental (OXY)
Per the Zacks analyst Occidental's margins could be adversely impacted by the rising global freight rates due to the U.S. sanction on Chinese supertanker operators.
Revenue & Regulatory Pressure Persist for Franklin (BEN)
Per the Zacks analyst, pressure on investment management fees amid muted AUM growth along with impact of new regulations continue to pose concerns for Franklin.
Higher Input, Maintenance Costs Ail Domtar Corporation (UFS)
Per the Zacks Analyst, higher maintenance costs owing to annual shutdowns of major facilities, rising raw material costs and unfavorable foreign currency will impact Domtar's results.
Occidental Petroleum Corporation (OXY) : Free Stock Analysis Report
Oracle Corporation (ORCL) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Intel Corporation (INTC) : Free Stock Analysis Report
ConocoPhillips (COP) : Free Stock Analysis Report
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research